JP2014523871A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014523871A5 JP2014523871A5 JP2014514917A JP2014514917A JP2014523871A5 JP 2014523871 A5 JP2014523871 A5 JP 2014523871A5 JP 2014514917 A JP2014514917 A JP 2014514917A JP 2014514917 A JP2014514917 A JP 2014514917A JP 2014523871 A5 JP2014523871 A5 JP 2014523871A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- seq
- functional
- agent
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161495868P | 2011-06-10 | 2011-06-10 | |
| US61/495,868 | 2011-06-10 | ||
| US201261613856P | 2012-03-21 | 2012-03-21 | |
| US61/613,856 | 2012-03-21 | ||
| PCT/US2012/041804 WO2012170977A1 (en) | 2011-06-10 | 2012-06-10 | Modulation of pancreatic beta cell proliferation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014523871A JP2014523871A (ja) | 2014-09-18 |
| JP2014523871A5 true JP2014523871A5 (enExample) | 2015-06-18 |
Family
ID=47296512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014514917A Pending JP2014523871A (ja) | 2011-06-10 | 2012-06-10 | 膵臓ベータ細胞増殖の調整 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20140303078A1 (enExample) |
| EP (1) | EP2717924A4 (enExample) |
| JP (1) | JP2014523871A (enExample) |
| CN (1) | CN104039357A (enExample) |
| AU (1) | AU2012267492A1 (enExample) |
| CA (1) | CA2838824A1 (enExample) |
| WO (1) | WO2012170977A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015509091A (ja) | 2012-01-09 | 2015-03-26 | ザ スクリプス リサーチ インスティテュート | ヒト化抗体 |
| CA2863224A1 (en) | 2012-01-09 | 2013-07-18 | The Scripps Research Institute | Ultralong complementarity determining regions and uses thereof |
| EP2943512A4 (en) * | 2013-01-11 | 2016-06-01 | California Inst Biomedical Res | BOVINE FUSION ANTIBODY |
| US20160067212A1 (en) * | 2013-03-15 | 2016-03-10 | Universite De Geneve | Use of insulin signaling antagonists, optionally in combination of transfection of non-beta cells, for inducing insulin production |
| CA2918370A1 (en) | 2013-07-18 | 2015-01-22 | Fabrus, Inc. | Humanized antibodies with ultralong complementarity determining regions |
| US9322037B2 (en) * | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| WO2015136055A1 (en) * | 2014-03-12 | 2015-09-17 | Neurimmune Holding Ag | Novel compounds capable of antagonizing islet amyloid polypeptide (iapp) induced beta-cell damage and impaired glucose tolerance |
| EP3201225B1 (en) * | 2014-10-03 | 2020-08-19 | NGM Biopharmaceuticals, Inc. | Angptl8 polypeptide and its use for treatment of conditions associated with elevated triglycerides |
| TW201713690A (zh) * | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
| WO2017062363A1 (en) * | 2015-10-05 | 2017-04-13 | Joslin Diabetes Center | Methods of use of betatrophin |
| PT3387019T (pt) | 2015-12-09 | 2022-01-14 | Scripps Research Inst | Proteínas de fusão de imunoglobulina de relaxina e métodos de uso |
| AU2018366122A1 (en) | 2017-11-10 | 2020-04-23 | Ngm Biopharmaceuticals, Inc. | ANGPTL8-binding agents and methods of use thereof |
| US12508428B2 (en) | 2023-01-26 | 2025-12-30 | Medtronic, Inc. | Respiratory-based cardiac remodeling pacing therapy |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070055056A1 (en) * | 1997-03-07 | 2007-03-08 | Rosen Craig A | 251 human secreted proteins |
| CA2296398A1 (en) * | 1997-08-01 | 1999-02-11 | Genset | 5' ests for secreted proteins expressed in endoderm |
| US6875741B2 (en) * | 1998-09-02 | 2005-04-05 | Renuka Pillutla | Insulin and IGF-1 receptor agonists and antagonists |
| WO2005003766A2 (en) * | 2003-06-13 | 2005-01-13 | Whitehead Institute For Biomedical Research | Methods of regulating metabolism and mitochondrial function |
| AU2006223579A1 (en) * | 2005-03-11 | 2006-09-21 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
| WO2007039606A2 (en) * | 2005-10-05 | 2007-04-12 | Novo Nordisk A/S | Insulin receptor antagonists and related compositions, uses and methods |
| CN101130768B (zh) * | 2006-08-22 | 2010-05-12 | 复旦大学 | 核苷酸分子sr1b及其在制备抗糖尿病药物中的应用 |
| NZ575804A (en) * | 2006-09-13 | 2012-01-12 | Univ Columbia | Undercarboxylated/uncarboxylated osteocalcin increases beta-cell proliferation, insulin secretion, insulin sensitivity, glucose tolerance and decreases fat mass |
| US20090232893A1 (en) * | 2007-05-22 | 2009-09-17 | Bader Andreas G | miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
-
2012
- 2012-06-10 AU AU2012267492A patent/AU2012267492A1/en not_active Abandoned
- 2012-06-10 JP JP2014514917A patent/JP2014523871A/ja active Pending
- 2012-06-10 EP EP12797387.3A patent/EP2717924A4/en not_active Withdrawn
- 2012-06-10 CN CN201280036842.1A patent/CN104039357A/zh active Pending
- 2012-06-10 CA CA2838824A patent/CA2838824A1/en not_active Abandoned
- 2012-06-10 US US14/125,276 patent/US20140303078A1/en not_active Abandoned
- 2012-06-10 WO PCT/US2012/041804 patent/WO2012170977A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014523871A5 (enExample) | ||
| Joshi et al. | Mnk kinase pathway: Cellular functions and biological outcomes | |
| Zanotti et al. | Decorin and biglycan expression is differentially altered in several muscular dystrophies | |
| Dang et al. | Transfer of a human gene variant associated with exceptional longevity improves cardiac function in obese type 2 diabetic mice through induction of the SDF-1/CXCR4 signalling pathway | |
| RU2707531C2 (ru) | Модели рака и соответствующие способы | |
| Qiao et al. | Muscle and heart function restoration in a limb girdle muscular dystrophy 2I (LGMD2I) mouse model by systemic FKRP gene delivery | |
| Kang et al. | Exercise-induced Musclin determines the fate of fibro-adipogenic progenitors to control muscle homeostasis | |
| Wang et al. | Endostatin prevents dietary-induced obesity by inhibiting adipogenesis and angiogenesis | |
| TW200912000A (en) | Inhibitors of the binding between HDM2 and the proteasome | |
| Shao et al. | Characterization and phylogenetic analysis of Krüppel-like transcription factor (KLF) gene family in tree shrews (Tupaia belangeri chinensis) | |
| JP7477448B2 (ja) | Ａｌｋを調節する方法 | |
| JP2015504299A5 (enExample) | ||
| CN114045335A (zh) | circSpred1基因作为标志物在纤维化肝脏、肝癌的诊断和药物制备中的应用 | |
| Wu et al. | Type 3 IP3 receptor: Its structure, functions, and related disease implications | |
| Wang et al. | The cross-talk between PARylation and SUMOylation in C/EBPβ at K134 site participates in pathological cardiac hypertrophy | |
| AU2017248038A1 (en) | Methods of modulating BCKDH | |
| JP2020526554A (ja) | 疼痛を管理するための方法 | |
| JP2011501672A5 (enExample) | ||
| Day et al. | NFAT expression in human osteoclasts | |
| CA2988086C (en) | An engineered ccl20 locked dimer polypeptide | |
| Thomas et al. | The roles of the PDZ-containing proteins bridge-1 and PDZD2 in the regulation of insulin production and pancreatic beta-cell mass | |
| US11571462B2 (en) | Engineered CCL20 locked dimer polypeptide | |
| JP2020510611A (ja) | Ｆａｍ４６ａを調節する方法 | |
| JP2020515551A (ja) | Ａｎｋ１を調節する方法 | |
| Zhang et al. | A conserved hormonal signalling–H2A. Z axis rapidly reorganizes 3D chromatin interactions in adipocyte thermogenesis |